A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy


Engineering T cells with expressions of chimeric antigen receptor (CAR) redirect these cells to target tumours, making this a promising cell-based cancer therapy [1]. To engineer universal CAR T cells for allogeneic cell therapy, gene editing approaches [2] can be used to remove risks associated with graft-versus-host disease [3].

Complex gene editing in primary immune can be challenging for some conventional methods [4]. The LNPs use endogenous uptake pathways to deliver therapeutic RNAs, making this technology gentle to the cells.

Here we report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene